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GENERAL INTRODUCTION
  Pharmacokinetics and pharmacodynamic effects of drugs are infiuenced by multiple
process including absorption, distribution, metabolism and excretion. Recent
significant advances in the research and technology have demonstrated the expression
ofvarious metabolic enzymes and transporters in the small intestine and the liver, and
its important role in determining drug disposition and pharmacological effects.
Furthermore, recent studies have demonstrated that drug transporters are also
important determinations of drug disposition and response by affecting cellar exposure
and distribution. Therefore, the interplay between uptakelefflux transporters and
metabolic enzymes needs to be carefu11y investigated in order to obtain a better
understanding of molecular mechanisms underlying variable drug response.
  The intestinal absorption is determined by the physicochemical properties ofa drug,
such as its solubility, the permeability of epithelial cell membranes, and its first-pass
metabolism in the liver and small intestine. The most important factor involved in the
first-pass effect in the small intestine has been considered to be CYP3A and P-gp. In
addition, the importance of other efflux transporters, such as BCRP and MRP2, and
influx transporters, such as PEPT and ASBT, expressed on the apical membrane has
been recognized. CYP3A is responsible for the majority of phase I drug metabolism
and is predominantly expressed in the human small intestine and liver. In the liver,
metabolic enzymes such as CYP3A has been considered to play a significant role for
the drug metabolism. However, recent study demonstrates influx transporters
expressed on sinusoidal membrane is also important for the metabolism in the liver
because the inhibition of these influx transporters increases the plasma concentration
of drugs in the liver, causing adverse events.
  BCRP is expressed at the apical membrane in the small intestine and has been found
recently. The mRNA level of BCRP in human small intestine is the same or higher
compared to that of other efflux transportersi). Urquhart et al. and Yamasaki et al.
                                    i
demonstrated a prominent role of BCRP polymorphisms in the intestinal absorption of
SASP in humans2'3). Therefore, the probe substrate ofBCRP is required to examine
the relation between pharmacokinetics and drug efficacy.
  Sulfasalazine (SASP) has long been used in the treatment of inflammatory bowel
diseases such as ulcerative colitis and Crohn's disease, and rheumatoid disease4'5). A
recent study demonstrated that long-term treatment ofhuman T-cells with SASP causes
the development of cellular drug resistance that is mediated by the induction ofBCRP,
suggesting that SASP is a substrate of human BCRP6). Furthermore, animal studies
using Bcrp'i- mice have shown the area under the plasma concentration (AUC) of SASP
after oral administration was 111-fold higher in Bcrp-i' mice compared with wild-type
mice, whereas the AUC of SASP after intravenous administration was only 13-fold
higher in Bcrp'!' mice7). These results suggest that Bcrp limits oral absorption of
SASP in the intestine. However, the recent report demonstrated the involvement of
MRP28'9) and an influx transporter in the intestinal absorption ofSASP iO). Therefore,
to elucidate the mechanism of intestinal absorption of SASP is important to use it as
the probe substrate ofBCRP. In chapter 1, the intestinal absorption characteristic of
sulfasalazine (SASP) was investigated.
  In chapter 2, the mechanism of ritonavir (RTV) boosting using each probe substrate
was investigated. RTV boosting is a drug therapy used in the treatment of HIV that
utilizes the principal of drug-drug interaction. RTV was first developed as an HIV
protease inhibitor (PI) and used for a single PI treatment. However, since its potent
inhibitory effect on the CYP3A was clarified, RTV has been used in multidrug
treatment regimens for HIV to obtain an adequate plasma concentration for effective
anti-HIv activityii'i2). In addition, the inhibitory effects of RTV to various effiux
transporters such as P-gp, BCRP, MRP2, and OATP were also reportedi3,i4,iS•i6).
Therefore, RTV boosting involves multiple mechanisms. The contribution of RTV to
the first-pass effect in the small intestines and livers of mice was investigated by using
several probe substrates.
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Chapter 1
Studies on the intestinal absorption characteristics of
cancer resistance protein (BCRP) substrate
sulfasalazine, a breast
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1. Introduction
  In this chapter, I investigated the characteristic of SASP, which is used as a probe
substrate ofBCRP, in the small intestinal absorption.
  After oral administration, SASP is broken down into sulfapyridine and
5-aminosalicylic acid by bacterial azo reductases in the colon and cecumi7'i8).
5-aminosalicylic acid is effective for inflammatory bowel diseases, while SASP and
sulfapyridine are effective for rheumatoid diseasei9'20'2i). The targeting of sAsp to
the colon is critical for demonstrating its pharmacological action.
  In humans, the bioavailability of orally administered SASP is less than 150/o22).
The cause of low bioavailability of SASP has been investigated and was attributed to
low solubility and poor permeability23). However, the recent study demonstrated that
SASP is a substrate ofthe efflux transporter, BCRP 6). More recently, Kusuhara et al.
reported the non-linearly in AUC of plasma SASP concentration between microdose
and therapeutic dose in the clinical study. As one ofpossible mechanisms underlying
the nonlinear pharmacokinetics of SASP, the saturation of the influx transporter, was
considerediO). However, the contribution ofinflux transporters on the intestinal SASP
absorption has not been elucidated in detail, and only the limited information is
available on the characterization of SASP intestinal absorption. Therefore, to
elucidate the mechanism of SASP in the small intestine is important to use a probe
substrate of BCRP. Thus, this study aimed to examine the intestinal absorption of
SASP by using everted sacs from wild-type and Bcrp-i- mice.
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2. Materials and Methods
   2.1 Materials
  SASP was purchased from Sigma-Aldrich (St Louis, MO, USA). Ko134 was
kindly provided by SOLVO biotechnology (Buda6rs, Hungary). All other chemicals
were of analytical grade and are commercially available.
   2.2 Animals
  Male ddY mice were purchased from Sankyo Labo Service Corp. (Tokyo, Japan).
Female Bcrp-i' mice were purchased from Taconic Farms (Germantown, NY, USA) and
were bred by Shimizu Laboratory Supplies Co., Ltd. (Kyoto, Japan). Age-matched
wild-type mice (FVB strain) were purchased from CLEA Japan (Tokyo, Japan). All
mice (10-40 weeks) were housed in rooms maintained at 23 OC and 55Å}5 O/o relative
humidity, and were allowed free access to food and water during the acclimatization
period. The animal work was performed at Hoshi University and complied with the
regulations of the Committee on Ethics in the Care and Use of Laboratory Animals.
   2.3 Preparation of everted mouse ileum sacs
 Everted sacs were prepared by a modification of the procedure described
previously24). Mice were anesthetized with ether and sacrificed by exsanguination of
the abdominal aorta. The ileum was removed immediately and rinsed in ice-cold
Krebs-Ringer-Henseleit bicarbonate buffer (KRB; 118 mM NaCl, 4.75 mM KCI, 2.50
mM CaC12, 1.19 mM KH2P04, 1.19 mM MgS04, 25 mM NaHC03, 11 mM D-glucose,
pH 6.5). Approximately 5-cm segments ofthe ileum was isolated and everted using a
stainless steel rod. Polyethylene tubes were inserted into both ends of the everted
segments and ligated.
   2.4 In vitro absorptive transport (mucosal-to-serosal) study using everted
         mouse ileum sacs
The everted sac was placed in 30 mL of KRB and gassed with 021C02 (95:5) at 370C.
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The everted ileum was fi11ed initially with 1.5 mL of KRB and perfused with the buffer
at O.1 mLlmin using an infusion pump (KD Scientific Inc., Holliston, MA, USA)
throughout the transport study. After preincubation in the buffer containing 2 pM
Ko1341 DMSO or DMSO for 30 min, SASP was added to the mucosal side to give a
final concentration of O.1, O.3, 1, 3 or 50 pM. The outflow perfusate was then
collected for 5 min at 15 minute intervals for up to 90 min.
  The absorptive clearance of SASP in the everted sac was calculated according to the
following equation:
           Absorption rate = (CoutXQ) 1 L
           Absorptive clearance = Absorption rate 1 Cm
where Cout represents the SASP concentration in the outflow solutions, Q is the
perfusion rate (O.1 mLlmin), L is the length of the intestinal segment, and C. is the
concentration of SASP in the mucosal medium.
   2.5 Quantification of SASP concentration in samples
   The SASP concentration was analyzed by LC-MSIMS in turbo ion spray negative
ion mode equipped with the Prominence LC system (Shimadzu Co., Kyoto, Japan)
coupled to an API4000 mass spectrometer (AB SCIEX, San Jose, CA, USA). The
mass transition was from mlz 397 to 197. ACAPCELL PAK MGII Cis (2.1Å~50 mm,
5 pm; Shiseido Co., Ltd., Tokyo, Japan) maintained at 400C was used for the
chromatographic separation. The LC separation was achieved using a mobile phase
comprising of 10 mM ammonium acetate (pH 8) and acetonitrile (2:8, vlv) at a flow
rate ofO.2 mLlmin. The data acquisition was performed using Analyst ver. 1.4.2 (AB
SCIEX, San Jose, CA, USA).
   2.6 Statistical analysis
 Each value is expressed as the mean Å} standard error (S.E.) of 4-7 determinations.
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For group comparisons, ANOVA with a one-way layout was applied. Significant
differences in the mean values were evaluated by Student's unpaired t-test or Dunnett's
test for multiple comparisons. Ap value of less than O.05 was considered significant.
3. Results
  In wild-type mice, the intestinal absorption rate of 10 pM SASP reached a plateau at
60 min in absence and presence of2 pM Ko134, a known inhibitor ofBcrp (Figure IA).
The absorptive clearance at 60 min was O.14 pLlminlcm in the absence of Ko134.
The reported ICso value for the inhibition of BCRP by Ko134 is O.07 pM25).
Therefore, we used 2 pM Ko134 to inhibit completely the efflux transport by Bcrp.
The absorptive clearance was increased by 4.8-fold in the presence of Ko134 (Figure
IB). These results indicate that Bcrp limits the intestinal absorption of SASP as
reported previously.
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Figure 1
(A)Intestinal absorption rate of SASP (10 pM) in the ileum of wild-type mice with
   or without Ko134
   The data are expressed as mean Å} S.E. (n=3-4). *pÅqO.05
(B)Steady-state absorptive clearance of SASP (at 60 min) in the ileum of wild-type
   mice with or without Ko134
   The data are expressed as mean Å} S.E. (n=4).
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  The intestinal SASP absorption was also examined at various SASP concentrations.
In wild-type mice, the absorptive clearance of SASP was similar in the range of O.1 to
50 pM (Figuer 2). By contrast, the absorptive clearance of SASP decreased
significantly along with the SASP concentration in the mucosal side in the presence of
Ko134 (Figure 3). Such concentration dependence in the absorptive clearance of
SASP was also observed in Bcrp-/t mice (Figure 4). Thus, the saturation of the
absorptive rate at a high concentration of SASP in the presence of the specific Bcrp
inhibitor and in Bcrp-/' mice suggests the involvement of some influx transporters in
the absorption of SASP.
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Figure 2
Steady-state absorptive clearance of SASP at various concentrations in the everted
ileum sac in wild-type mice
The data are expressed as mean Å} S.E. (n=4).
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Figure 3
Steady-state absorptive clearance of SASP at various concentrations in the everted
ileum sac in the presence of Ko134 in wild-type mice
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Figure 4
Steady-state absorptive clearance of SASP at various concentrations in the everted
                -/- -ileum sac in Bcrp
                  mlce
The data are expressed as mean Å} S.E. (n=4-7). *pÅqO.05
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4. Discussion
  Our data suggest that both influx and efflux transporters are involved in the
absorption of SASP. As a result, each process of intestinal absorption of SASP
mediated by influx and efflux transporters was not observed clearly in wild-type mice.
Recently, involvement of MRP2 in the intestinal absorption of SASP has been
reported8'9). However, considering the affinity and the expression of these
transporters 26), the contribution of Mrp2 to SASP intestinal absorption is considered to
be low in our study because we used the ileum for the experiments.
  Kusuhara et al. reported that SASP was a substrate of OATP2B1 and its Km was 1.7
pMiO). In our study, the Km of influx transporter mediated SASP absorption was
estimated to be approximately lpM (Figure 3) and this value was almost the same
value calculated in their study. Jani et al. investigated the detailed kinetic
characterization of SASP using membrane vesicles prepared from mammalian cells
selectively overexpressing ABCG2, and calculated Km of SASP to ABCG2 was about
O.7 pM27). Therefore, the infiux and efflux transporters involved in SASP absorption
may have similar affmity for SASP.
  In clinical use, the intestinal concentration of SASP was calculated to be 2.5 mM
when the intestinal volume was assumed to be as 1.92 L28), which was far greater than
its Km to OATP2Bl and saturated. Under this estimation, SASP may inhibit the
absorption of OATP2Bl substrate drugs. In a clinical study of talinolol, which is
substrates ofOATPIA2 and OATP2B1 in human and Oatpla5 in rat29'30), concomitant
use of SASP decreased the AUC for talinolol3i). Although this mechanism is unclear,
the drug-drug interaction must be noted when SASP is coadministered with a substrate
of OATP2Bl. Furthermore, in the clinical study of Kusuhara et al., the
dose-normalized AUC of SASP was much smaller in therapeutic dose than that in
microdose. As they described in their reports, BCRP is considered not to be saturated
even in the therapeutic dose and this nonlinearity is caused by the saturation of the
influx transporter OATP2Bl at a therapeutic dose. Therefore, the absorption ofSASP
is mainly regulated by BCRP in clinical use.
                                    11
5. Conclusion
  The intestinal absorption of SASP involved not only BCRP but also the influx
transporter. In the clinical use, the contribution of this influx transport on the
intestinal absorption of SASP may be low. However, the drug-drug interaction must
be noted when SASP is coadministered with the substrate of this influx transporter.
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                             Chapter 2
Analysis of the pharmacokinetic boosting
bioavailability of drugs in mice
effects of ritonavir on oral
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1. Introduction
  In the previous chapter, the elucidation of the characteristics of SASP could explain
the findings in the clinical study. In this chapter, the inhibition mechanisms involved
in the RTV boosting was investigated. RTV dramatically increases the bioavailability
of a variety of concurrently administered drugs by inhibition of metabolic enzymes and
drug transporters. In this study the extent to which ritonavir's inhibition of drug
transporters andlor CYP3A contributes to the increased oral bioavailability in mice
was investigated.
  In antiretroviral therapies, adequate plasma concentrations of PIs are required for
their effective anti-HIV activity. The potent inhibition of CYP3A in the small
intestine and liver by RTV improves the bioavailability of drugs and prolongs their
elimination half-lives. As a result, RTV boosting allows both dose and dosing
frequency of the concurrently administered PI to be reduced.
  Saquinavir (SQV) is also a highly selective HIV PI and is administered as one of the
RTV boosted PIs. The bioavailability of orally administered SQV was only 4 O/o in
healthy volunteers after a single dose and this poor bioavailability of SQV is attributed
to the extensive first-pass metabolism in the small intestine and liver, because SQV is a
substrate of CYP3A32). The concurrent administration of SQV with RTV enhances
the plasma concentration of SQV, and so SQV is used as a combination therapy with
RTV. The boosting effect of RTV is considered to be mediated through its inhibitory
effect on CYP3A. However, RTV also inhibits many transportersi3'i4'i5'i6) and sQv
is also a substrate ofP-gp 33). Therefore, the inhibition ofP•-gp by RTV in the small
intestine might enhance the bioavailability of SQV. Recently, it was reported that
SQV is a substrate of OATPIBI and OATPIB33`). OATPIBI and OATPIB3 are
influx transporters and localized on the basolateral membrane of hepatocytes. As
observed in the drug-drug interaction between cerivastatin and gemfibrozi135), the
inhibition of the influx transporters expressed on sinusoidal membrane increases the
plasma concentration, causing adverse events.
  In this chapter, the contribution of the RTV effect on the first-pass effect in the small
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intestines and livers of mice was assessed. The RTV boosting effects on several
probe substrates were also investigated. In addition, the in vitro study using mouse
intestinal and liver microsomes were performed to confirm the results obtained from
the in vivo study.
15
2. Materials and Methods
   2.1 Materials
  RTV purchased as Norvir@ (80 mglmL) from Abbot Laboratories (Abbott Park, IL,
USA) and midazolam (MDZ) as Dormicum Injection@ (5 mglmL) purchased from
Astellas Pharma Inc. (Tokyo, Japan) were used in the in vivo study. In the in vitro
study, RTV purchased from BIOTREND Chemikalien GmbH (Cologne, Germany) and
MDZ purchased from Wako Pure Chemical Industries, Inc. (Tokyo, Japan) were used.
SQV was purchased from Sequoia Research Products Ltd. (Pangbourne, UK) and
pravastatin (PRV) sodium was purchased from Wako Pure Chemical Industries, Inc.
Itraconazole (ITZ) was purchased from Sigma-Aldrich Co. (St Louis, MO, USA).
Fexofenadine hydrochloride was purchased from Tronto Research Chemicals Inc.
(Ontario, Canada). All other chemicals were of analytical grade and are
commercially available.
   2.2 Animals
  Female ddY mice (11-13 weeks old) were purchased from Sankyo Labo Service
Corp (Tokyo, Japan). The mice were housed in rooms maintained at 23 OC and 55 Å}
5 O/o relative humidity, and allowed free access to food and water during the
acclimatization period. In the in vivo study, the mice were fasted overnight for at
least 12h, with free access to water. The animal study was performed at Hoshi
University and complied with the regulations of the Committee on Ethics in the Care
and use of Laboratory Animals.
   2.3 In vivo studies
2.3.1 Preparation of dosing solutions .
  The SQV dosing solution was prepared as described previously36). Briefly, SQV was
dissolved in an 8 O/o ethanol14.2 O/o glucose solution for intravenous administration and in a
16.4 O/o ethanoY3 O/o glucosel15.6 O/o Cremophor EL solution for oral administration. Norvir@
was diluted with ethanol and water to prepare a 8 mglmL solution. As the control vehicle for
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Norvir@, a 43 O/o(vlv) ethanol solution containing Cremophor EL (105 mglmL), propylene
glycol (O.25 mglmL), peppermint oil (3.5 mglmL), and water-free citric acid (2.8 mglmL)
were used. This control vehicle was 10-fold diluted by ethanol and water to contain the
same volume ofvehicle constituents as RTV dosing solution. For the dose-dependency of
RTV inhibition effect study, Norvir(!D was diluted with control vehicle to prepare 2.4, 8 and 40
mglmL solutions. Then, these solutions were diluted with ethanol and water to make each
RTV dosing solution (O.24, O.8 and 4 mglmL). The dosing solution for each probe substrate
was prepared as follows. Fexofenadine hydrochloride and pravastatin sodium were
dissolved in water to concentrations of 1.5 and 20 mglmL, respectively. Dormicum
Injection@was diluted with water to concentration of 3 mglmL and used as the MDZ dosing
solution. The ITZ dosing solution was prepared as described previously37). Briefly, 20 mg
of ITZ was dissolved with O.1 mL of 12 N HCI, and 1.75 mL ofpolyethylene grycol 400 and
O.15 mL of 8 N NaOH were added to prepare a 10 mglmL ITZ solution. As the control
vehicle for ITZ, the solution which contains the same contents of vehicle constituents was
used.
2.3.2 Effect of RTV on the pharmacokinetic of SQV
  The dose dependent effects of RTV on the pharmacokinetics of SQV were
investigated. The administered doses of RTV were set at 1.5, 5, 25 and 50 mglkg.
The dose of 1.5 mglkg is the clinically relevant dose (RTV boosting dose : 100 or 200
mgldose, i.e.,1.5-3 mglkg for a 70 kg man). SQV (20 mglkg) was administered orally
30 min after the oral administration of RTV. In addition, to investigate the
contribution of RTV on the first-pass effect in the liver and small intestine, SQV was
administered orally (20 mglkg) or intravenously (2 mglkg) 30 min after the oral
administration of 5e mglkg RTV. For oral administration, mice were given each
solution by sonde needle into the stomach. For intravenous administration, each
solution was injected into the tail vein ofmice. Thirty pL of blood was taken from
the tail vein by using micro-haematocrit capillary tubes and centrifuged at 15,400Å~g
for 10 min to obtain the plasma samples. The plasma samples were stored at -20 OC
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until analysis.
2.3.3 Effect of RTV on the pharmacokinetic ofprobe substrates
  FEX (10 mglkg) was used as the probe substrate for P-gp, MDZ (10 mglkg) for
CYP3A, and PRV (100 mglkg) for OATPIBI. Each probe substrate was administered
orally 30 min after the oral administration of 1.5 or 50 mg!kg RTV. The effect of ITZ,
an inhibitor of CYP3A in humans, on the pharmacokinetics of SQV was also
investigated. SQV (20 mglkg) was administered orally 30 min after the oral
administration of 50 mglkg ITZ. Thirty pL ofblood was taken from the tail vein by
using micro-haematocrit capillary tubes and centrifuged at 15,400Å~g for 10 min to
obtain the plasma samples. The plasma samples were stored at -20 OC until analysis.
2.3.4 Quantification of the plasma concentration of SQV, FEX, MDZ and PRV
  For the determination of each substrate concentration in plasma, 100 pL of
acetonitrile was added to the 10 pL ofplasma sample. After the protein precipitation
by vortex mixing and centrifugation, 80pL of supernatant was evaporated at 40 OC
under nitrogen. The residue was reconstituted with the 100 pL of mobile phase and
subjected to LC-MSIMS analysis on an API4000 system (AB SCIEX, Foster City, CA,
USA) equipped with the Prominence LC system (Shimadzu Co., Kyoto, Japan). The
LC-MSIMS conditions are summarized in Table 1. The data were acquired with
Analyst ver. 1.4.2 (AB SCIEX). The limit of quantification for all compounds was
1nglmL.
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Tablel LC-MS/MS conditions for each substrate
Compounds Column Mobile phase Ionization rn/z
SQV
FEX
MDZ
CAPCELL PAK MGII C18
(2.1x50 mm, 5 pm)
(Shiseido Co., Ltd., Tokyo, Japan)
10 mM acetic acid in 400/o acetonitrile Positive 671 to 570
10 mM acetic acid in 350/e acetonitrile Positive 502 to 466
10 mM acetic acid in 300/o acetonitrile Positive 326 to 291
PRV
Hypersil Gold (2.1Å~50 mm, 5 pm)
                        10 mM acetic acid in 400/o acetonitrile Negative
(Thermo fisher Co., Ltd., Tokyo, Japan)
423 to 321
   2.4 In vitro studies
2.4.1 Preparation of mouse microsomes
  Pooled mouse liver and intestinal microsomes were prepared according to a
previously reported method38). Briefly, livers and intestinals were homogenized
separately in three volumes of ice-cold buffer (50 mM Tris-HCI, pH7.4) containing
150 mM KCI, 1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 1 mglmL trypsin
inhibitor, 10 pM leupeptin, O.04 unitlmL aprotinin, 1 pM bestatin, and 20 O/o(v/v)
glycerol using Teflon-tipped pestle. The homogenates were centrifuged at 9,OOOXg
for 20 min at 40C, and the supernatants were then centrifuged at 105,OOO Å~ g for 60 min
at 40C. The microsomal pellets were resuspended in the same buffer and stored at
-
80 OC. The protein concentrations were determined using a BCA Protein Assay Kit
(Pierce Chemical, Rockford, IL, USA).
2.4.2 Inhibition study
  In preliminary experiments, we confirmed that substrate depletion increased
proportionally with time (to 20 min) and with protein concentration (in the range of O. 1
to 1 mglmL protein) for both the liver and intestinal microsomes.
  The mouse liver and intestinal microsomes were incubated with SQV or MDZ with
or without an inhibitor in an NADPH-generating system containing 2.5 mM NADP, 25
mM glucose 6-phosphate, 2 units of glucose-6-phosphate dehydrogenase, and 10 mM
MgC12 in a total volume of O.2 mL of 100 mM phosphate buffer (pH7.4). After
preincubation for 5 min at 370C, the reaction was initiated by the addition of the
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NADH-generating system. After incubation, the reaction was terminated by the
addition of O.4 mL of ice-cold acetonitrile and briefiy vortex mixed. The samples
were centrifuged at 15,400Å~g for 15 min to precipitate the protein. The supernatant
was evaporated at 40 OC under nitrogen. The residue was reconstituted with the
mobile phase and the depletion of SQV or MDZ was analyzed by HPLC-UV.
2.4.3 Quantification of SQV and MDZ concentration in the in vitro samples
  HPLC was performed with a Prominence LC system (Shimadzu Co.), equipped with
a TSKgel@ ODS-100V column (2.1Å~50 mm, 5 pm; Tosoh Co., Tokyo, Japan) for SQV
and a CAPCELL PAK MGII C18 column (2.1Å~50 mm, 5 pm; Shiseido Co., Ltd., Tokyo,
Japan) for MDZ. 10 mM Na2HP04 in 35 O/o acetonitrile was used as the mobile phase
for SQV and 10 mM phosphate buffer (pH6) in 40 O/o acetonitrile were used as the
mobile phase for MDZ. The flow rate was O.2 mLlmin at 40 OC and the elution was
monitored at wavelengths of254 nm for SQV and 230 nm for MDZ.
   2.5 Pharmacokinetic calculations
2.5.1 In vivo study
  The Cma. was obtained directly from the raw data. The area under the plasma
concentration-time curve from time O to the last time point (AUCo-t) was calculated
using the linear trapezoidal rule. The AUCinf, with extrapolation to infinity was
calculated by dividing the last measured concentration by the elimination rate constant,
which was determined as the slope ofregression for the terminal log-linear portion of
the concentration versus time curve. The bioavailability (F), hepatic availability (Fh),
fraction absorbed (F.), and intestinal availability (Fg) were calculated using equations
1-4. The blood-to-plasma ratio (Rb) and the hepatic blood flow (Qh) values used were
O.639) and 5.4 Llhlkg40), respectively. Hepatic clearance was regarded as the total
clearance because the urinary excretion was negligible32).
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F=(AUCpo ' Dosei.)1(AUCi. ' Dosep.) (eq.1)
CLtot=CLh==Doseivl(AUCiv ' Rb ) (eq.2)
Fh-1 -CLhlQh (eq.3)
Fa'Fg =FIFh(eq.4)
2.5.2 In vitro study
 The initial reaction rate was determined under linear conditions. The inhibition
constant (ki) was determined by plotting the slope of the Dixon plot versus inhibitor
concentratlon.
The increase in the AUC (R) caused by the drug-drug interactions was calculated with
eq.5 for the intravenous administration and with eq.6 for the oral administration4i).
R=1+(Ii.,. ' Fh) 1 ki (eq.5)
R=1+Ii.,.1 ki (eq.6)
Where, Iin,u=(Imax+Ka ' Fa ' Fg ' DIQh) ' fb
Imax represents the maximum concentration of the inhibitor in the systemic blood and
used Cmax of inhibitor corrected Rb. The first-order rate constant (Ka), the fraction
absorbed from the gastrointestinal tract into the portal vein (Fa), and the unbound
fraction in the blood (fb) used for calculations are summarized in Table 2.
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Table2 Parameters used in the prediction of the increased in the AUC from ki
      values
Parameters Unit RTV ITZ
Imax pM 24 242)
Ka •- O.O07 O.O044)
Fa'Fg
-
O.8 1
Qh Llhlkg 5.440) 5.440)
Rb
-
O.743) O.644)
fb
-
O.02643) O.O0337)
Imax represents the maximum concentration of the inhibitor in the systemic blood and
used Cmax of inhibitor corrected Rb (The Cm.. for RTV was obtained from our study).
The Ka and Fa'Fg for RTV was calculated using the AUCi.f in this study and
bioavailbility45). The maximum value was used as Fa'Fg for ITZ.
   2.6 Statistical analysis
  Each value is expressed as a mean Å} standard deviation (SD). Statistical
significance was examined by one-way ANOVA followed by Dunnett's post hoc
multiple-comparison test. Ap value ofless than O.05 was considered significant.
3. Results
   3.1 Effect of RTV on the pharmacokinetics ofSQV
  RTV increased the Cm,. and AUCi.f for SQV in a dose-dependent manner. The
AUCinf for SQV was increased three-, 26-, 241-, and 325-fold by the coadministration
of 1.5, 5, 25, and 50 mglkg RTV, respectively. The plasma concentration-time
profiles and pharmacokinetic parameters are shown in Figure 1 and Table 3,
respectively. High dose of RTV was administered and significant interaction was
observed in this study, however, the animals were well tolerated.
  To assess the effect of RTV on the first-pass effect in the liver and small intestine,
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Fa'Fg and Fh were calculated from the pharmacokinetic parameters after the
intravenous and oral administration of SQV with and without 50 mglkg RTV. The
plasma-concentration time profiles and pharmacokinetic parameters for SQV are
presented in Figure 2 and Table 4, respectively. After the intravenous administration
of SQV, the coadministration of RTV caused only fivefold increase in the AUCinffor
SQV. In contrast, after the oral administration of SQV, the AUCinf increased
dramatically (325-fold) with the coadministration of 50 mg/kg RTV. As a result, the
bioavailability of orally administered SQV increased from O.O093 to O.675. Fh and
Fa'Fg for SQV were increased 1.7- and 38-fold, respectively, with the coadministration
of RTV.
                                                   -LX- RTV 1.5 mgtkg
                                                   ---- RTV 5 mg/kg
      AIOOO -O- RTV 2S mglkg
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Figure 1
Plasma SQV concentration - time profiles after oral administration of SQV with
various dose of RTV
SQV (20 mg/kg) was given orally after oral administration of RTV at a dose of 1.5, 5,
25 and 50 mg!kg. Each point represents the mean Å} SD (n=3).
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Table3 Pharmacokinetic parameters for SQV after oral administration
      with or without oral administration of RTV in mice
of SQV
RTV Cmax AUCinf
Control 65.6 Å} 43.9 165.6 Å} 128.7
1.5 266.6 Å} 43.5
Fold increase 4
500.7 Å}
3
78.0
5 1969.9 Å}
30
1829.5
Fold increase
4335.0 Å}
26
3580.6
25 6921.5
Fold increase
        deÅ} 2691.7
106
39966.6 Å}
241
      t21426.0
50 4779.7 Å}
 73
1151.2
Fold increase
* 53850.1 Å}
325
      *12758.9
Values are mean Å} SD (n=3-4). *: pÅqO.Ol
24
?
-oo
`
g
'g
/-9
s,
100000
E
-ua
"
E
r;
tt
ts
=
oo8•
10000
1000
100
10
1
10000
1000
100
10
1
o
tWith RTV
o 4
 Time (hr)
   (A)
16 20 24
O 4 8 12 16  20 24 28 32 36 40 44 48
Time (hr)
(B)
Figure 2
Plasma SQV concentration - time profiles after intravenous (A) or oral (B)
administration of SQV with or without RTV
SQV was given intravenously (2 mglkg) or orally (20 mglkg) after oral administration
of RTV at a dose of 50 mglkg. Each point represents the mean Å} SD (n=4-6).
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Table4Pharmacokinetic parameters of SQV after intravenous and oral
      administration of SQV with or without oral administration of RTV in mice
Cmax Tmax AUCo-t AUCinf
Oral
(nglmL) (h) (ng•h!mL) (ng•hlmL)
Control 65.6 Å}43.9 O.6 Å} O.7 153.4Å}133.1 165.6Å} 128.7
with
** ** ** **4779.7 Å}1151.2 7.0 Å} 2.0 53839.0Å}12757.3 53850.1Å} 12758.9
RTV
Intravenous
AUCo.24
(ng•hlmL)
AUCinf
(ng•hlmL)
CLtot
(Llhrlkg)
Control 1516.7Å}608.0 1525.4Å}606.7 2.46 Å}O.93
withRTV O.47 Å}O.16*
Values are mean Å} SD (n=4-6). *:pÅqO.05 **:pÅqO.Ol
   3.2 Effect of RTV on the pharmacokinetics of probe substrates
  The effects of RTV on the pharmacokinetics of each probe substrate were
investigated. The plasma concentration-time profiles and pharmacokinetic
parameters for each probe substrate are shown in Figures 3 - 5 and Tables 5 - 7,
respectively. At the clinically relevant dose (1.5 mglkg), the AUCi.ffor FEX was not
affected with the coadministration of RTV. However, the AUCi.f for MDZ and PRV
increased twofold when they were coadministered with 1.5 mglkg RTV. The AUC inf
for MDZ, FEX and PRV increased five-, 13- and sevenfold, respectively, when they
were coadministered with 50 mglkg RTV.
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Figure 3
Plasma MDZ concentration - time profiles after oral administration of MDZ with
or without RTV
MDZ (1O mglkg) was given orally after oral administration of RTV at a dose of 1.5 and
50 mglkg. Each point represents the mean Å} SD (n=3).
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Figure 4
Plasma FEX concentration - time profiles after oral administration of FEX with or
without RTV
FEX (20 mglkg) was given orally after oral administration of RTV at a dose of 1.5 and
50 mglkg. Each point represents the mean Å} SD (n== 3).
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Figure 5
Plasma PRV concentration - time profiles after oral administration of PRV with
or without RTV
PRV (100 mglkg) was given orally after oral administration of RTV at a dose of 1.5
and 50 mglkg. Each point represents the mean Å} SD (n=3).
Table5 Pharmacokinetic parameters of MDZ after oral administration
      with or without oral administration of RTV in mice
of MDZ
MDZ
RTV Cmax AUCinf
Control 226.7 Å} 100.6 245.2 Å} 88.3
1.5
Fold increase
371.3 Å} 252.1
      2
463.4 Å}
      2
296.3
50
Fold increase
427.6 Å} 61.8
      2
1220.3 Å}
      5
    *117.9
Values are mean Å} SD (n=3). *pÅqO.O1
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Table6 Pharmacokinetic parameters of FEX after oral administration
with or without oral administration of RTV in mice
of FEX
FEX
RTV Cmax AUCinf
Control 85.6 Å} 28.9 542.3 Å} 211.7
1.5
Fold increase
63.5 Å} 14.6
     1
398.4 Å}
      1
84.6
50
Fold increase
939.8 Å} 42.9'
     11
7169.2 Å}
13
    *586.9
Values are mean Å} SD (n=3). * pÅqO.Ol
Table7 Pharmacokinetic parameters of PRV after oral administration
with or without oral administration of RTV in mice
of PRV
PRV
RTV Cmax AUCinf
Control 737.3 Å} 557.1 636.3 Å} 97.1
1.5 534.9 Å}
      1
58.1
Fold increase
1045.7 Å}
2
164.2
50
Fold increase
2433.7 Å} 1532.3
       3
4604.1 Å}
7
     *1736.3
Values are mean Å} SD (n==3). *pÅqO.O1
   3.3 Effect of lTZ on the pharmacokinetics of SQV
  The inhibitory effect of 50 mglkg ITZ on the pharmacokinetics of SQV after its oral
administration was investigated. The plasma concentration-time profile and
pharmacokinetic parameters are shown in Figure 6 and Table 8, respectively. There
was no significant difference in the Cma. and AUCi.f after treatment with and without
50 mglkg ITZ and this result indicates that cyp isoforms other than cyp3a are involved
in the metabolism of SQV in mice.
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Figure 6
Plasma SQV concentration - time profiles after oral administration of SQV with
or without ITZ
SQV (20 mglkg) was given orally after oral administration of ITZ at a dose of 50
mglkg. Each point represents the mean Å} SD (n=3).
Table8 Pharmacokinetic parameters of SQV after oral
with or without oral administration of ITZ in mice
administration of SQV
SQV
 ITZ
(mglkg)
 Cmax
(nglmL)
 AUCinf
(ng 'hlmL)
Control 50.6 Å} 332 86.7 Å} 65.8
50
Fold increase
70.0 Å} 19.9
    1.4
138.6 Å} 55.0
1.6
Values are mean Å} SD (n=3).
   3.4 In vitro study
  Before performing the inhibition study, the apparent Km of SQV in the mouse liver
was calculated and the concentration of substrate in the inhibition study was set below
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the Km value (data not shown). The same concentration was used in the inhibition
study with mouse intestinal microsomes. Figures 7 and 9 show the Dixon plots for
the inhibition by RTV of SQV or MDZ metabolism, respectively, in mouse liver and
intestinal microsomes. The SQV and MDZ concentrations used were O.25, O.5 and 1
pM. The inhibition by RTV or ITZ was considered to be competitive or
non-competitive. The Ki values for the inhibition of SQV metabolism by RTV were
95 and 75 nM in the liver and intestinal microsomes, respectively (Table 8). The Ki
value for the inhibition of MDZ metabolism was 65 nM in both the liver and intestinal
microsomes (Table 9). The inhibitory effect of ITZ on the metabolism of SQV was
also investigated (Figure 9). The Ki values were 3.6 and 2.7 pM in the liver and
intestinal microsomes, respectively.
  The fold increases in the AUC predicted from the in vitro study and their comparison
with the values observed in the in vivo study are shown in Table 10. A fourfold
increase in the AUC for SQV was predicted from the Ki value using eq.5, which is
close to the value observed after the intravenous administration of SQV. In contrast,
a ninefold increase in the AUC for SQV was predicted from the Ki value using eq.6.
The remaining increase in the AUC for SQV derived from the inhibition of metabolic
enzymes in the small intestine was estimated about 36-fold. This result indicates that
the effect of RTV was greater in the small intestine than in the liver, which consistent
with the results obtained in the in vivo study.
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Figure 7
Dixon plots for the inhibition of SQV metabolism by RTV in mouse liver (A) and
intestinal microsomes (B)
SQV (O.25, O.5, 1 pM) was incubated at 370C for 10 min with liver microsomes (O.2
mg lmL protein) (A) and 20 min with intestinal microsomes (O.2 mglmL protein) (B)
The data represents the mean of n=3.
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Figure 8
Dixon plots for the inhibition of MDZ metabolism by RTV in mouse liver (A) and
intestinal (B) microsomes
MDZ (O.25, O.5, 1 pM) was incubated at 370C for 5 min with liver microsomes (O.1 mg
lmL protein) (A) and 15 min with intestinal microsomes (O.2 mglmL protein) (B)
The data represents the mean of n=3.
                                  32
9 LO.
-1
7
5
År
s.pt
3
-
1
eo25 pM
.5 pM
pM
9 AO
11
7
s 5 e
1
-
1
eO.25 pM
.5pM
pM
          ConcentrationoflTZ(ILM) ConcentrationoflTZ(pM)
                   (A) (B)
Figure 9
Dixon plots for the inhibition of SQV metabolism by ITZ in mouse liver (A) and
intestinal (B) microsomes
SQV (O.25, O.5, 1 pM) was incubated at 370C for 10 min with liver microsomes (O.2
mg lmL protein) (A) and 20 min with intestinal microsomes (O.2 mgfmL protein) (B)
The data represents the mean ofn=3.
Table9 The ki values of SQV and MDZ inhibition by RTV and ITZ in mouse liver
      and intestinal microsomes
Substrates SQV SQV MDZ
Inhibitors RTV ITZ RTV
Livermicrosomes 95nM 3.7pM 65nM
Intestinal
.
mlcrosomes
75nM 2.6pM 65nM
Values are mean ofn=3.
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TablelO Comparison of the fold
and predicted value
increase in the AUC between observed value
Substrates SQV SQV MDZ
Inhibitors RTV ITZ RTV
FoldincreaseinAUC
(Observed) 325 2 5
Oral
FoldincreaseinAUC
(Predicted) 9 1 12
Intravenous
FoldincreaseinAUC
(Observed) 5 - -
FoldincreaseinAUC
(Predicted) 4 - -
The dosage ofeach substrate and inhibitor are follows.
SQV: 2 mglkg for intravenous administration and 20 mglkg for oral a
MDZ: 10 mglkg, RTV and ITZ : 50 mglkg
dministration,
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4. Discussion
  In this study, in vivo and in vitro experiments were performed in mice to clarify the
underlying mechanisms of RTV boosting. Escalating doses of RTV had
dose-dependent effects on the pharmacokinetics ofSQV. The increasing in the Cmax
for SQV reached a plateau at 25-50 mg/kg RTV and the AUCi.f showed a tendency to
increase even at 50 mglkg RTV. There was a threefold increase in the AUCi.ffor SQV
when administered with 1.5 mglkg RTV, the clinically relevant dose. In the clinical
dose, it is reported that the increase in the AUC for SQV at SQVIRTV doses of
12001100 mg is six- to sevenfold46'47). Therefore, our results indicate the effect of
RTV boosting is similar in humans and in mice.
  The contribution of 50 mglkg RTV boosting to the first-pass effect on SQV in the
small intestine and liver was accessed. As a result, F.'Fg increased 38-fold, whereas
Fh increased only twofold. These results suggest that RTV mainly influences the
first-pass effect in the small intestine, resulting in an increase in the bioavailability of
orally administered SQV.
  Factors affecting the first-pass effect in the liver are metabolic enzymes and drug
transporters. Among the metabolic enzymes in the liver, CYP3A is particularly
important because it is responsible for the majority of phase I drug metabolism
reaction, including those ofPIs. CYP3A is also an important factor in the first-pass
effect in the small intestine. In addition to the metabolic enzymes, the efflux
transporters localized in the apical membrane are also important factors in the small
intestine. Therefore, the inhibition of P-gplCYP3A in the small intestine and the
inhibition of CYP3A in the liver are considered to increase the oral bioavailability of
SQV. However, regarding to the probe substrate of CYP3A, the increase in the
AUCinf for MDZ after its oral administration with 50 mglkg RTV was only fivefold.
In addition, the increase in the AUC for SQV after its oral administration with ITZ was
only twofold, and did not differ significantly from the control. Yamano et al.
evaluated the extent of drug-drug interactions involving metabolic inhibition in the rat
liver37). In their report, the increase in the AUC for MDZ in the presence ofITZ was
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about twofold, which is consistent with our result of the inhibition study by ITZ.
  MDZ is predominantly biotransformed to the 1'-hydroxy MDZ rather than to
4-hydroxy MDZ in both humans and mice48). In humans, CYP3A mediates its
biotransformation to both 1'-hydroxy and 4-hydroxy MDZ. On the other hands, there
is a report that cyp3a mediates only its biotransformation to 4-hydroxy MDZ in mice,
and cyp isoforms other than cyp3a mediate its biotransformation to 1'--hydroxy MDZ49).
Furthermore, Waterschoot et al. even reported that MDZ metabolism was observed in
liver microsomes prepared from cyp3a-/' mice50). These data indicate a species
difference in the MDZ metabolism in mice and humans and suggest that the cyp
isoforms involved in the metabolism of SQV in mice differ from those involved in
humans.
  Perloff et al. reported that the Ki values for the inhibition by ketoconazole of
1'-hidroxy and 4-hydroxy MDZ biotransformation were 1.7 and O.066 pM, respectively,
in mouse liver microsomes. In humans, these Ki values were O.O054 and O.039 pM,
respectively49). These results show the Ki value for the inhibition by ketoconazole of
1'-hydroxy MDZ biotransformation in mice differed greatly from that in humans.
Moreover, the Ki value for the inhibition by ketoconazole of 1'-hidroxy MDZ
biotransformation was the same as our result for the inhibition by ITZ of SQV
metabolism. In addition, Yamano et al. determined the Ki value for the inhibition of
1'-hidroxy biotransformation by ketoconazole and ITZ, and they found those were the
same37). In our study, the inhibitory effect of RTV on the metabolism of SQV and
MDZ was the same. Therefore, RTV and ITZ inhibit the cyp isoforms involved in the
metabolism of SQV and MDZ, and these cyp isoforms may be the same or have a same
affinity to RTV or ITZ. Komura and Iwaki reported that the cyp mRNA expression
levels differ in the livers and small intestines of mice, and that cyp3a13 is
predominantly expressed in the small intestine and is responsible for the first-pass
metabolism ofCYP3A substrates in the mouse small intestine37)' They also evaluated
the relationships of the Km values for the CYP3A4 mediated biotransformations of 13
drugs in intestinal and liver microsomes, and a good relationship was observed,
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although the mRNA expression levels differed. This observation supports our finding
that the Ki values were the same for the liver and intestinal microsomes in the in vitro
study.
   When we considered a substrate of P-gp, there was no significant difference in the
Cmax or AUCinf for FEX when it was coadministered with 1.5 mglkg of RTV. In
humans, twofold increase in the AUC for FEX was observed when given with 100 mg
of RTV5i), so there are also species differences in the effects of RTV on the
pharmacokinetics of FEX. The oral bioavailability, Fa'Fg and Fh of FEX in humans
has been reported as O.28, O.31 and O.952), respectively. Therefore, it is estimated
that the maximum increase in the AUC for FEX is about threefold when the inhibition
by RTV is completed. In our study, the increase in the AUCinf for FEX in mice
coadministered with 50 mglkg RTV was 13-fold, which was higher than that estimated
for humans. In addition, it has been reported the oral bioavailability , Fa'Fg and Fh in
mice were O.O14, O.022 and O.64153), respectively. The maximum increase in the
AUC for FEX is estimated to be about 50-fold, with complete inhibition by RTV.
Therefore, even 50 mglkg RTV may not inhibit the first-pass effect in the small
intestine and liver completely in mice. Tahara et al. reported that the increase in the
AUC for FEX in Mdrlallb P-gp knockout mice was about sixfold54). Considering
our result and the very small F,'Fg values of FEX in mice, efflux transporters other
than P-gp may be involved in the intestinal absorption of FEX in mice. Bcrp and
Mrp2 are the efflux transporters expressed at the apical membrane in the mouse small
intestine. It has been reported that FEX is not a substrate of BCRP in human55).
Furthermore, Mrp2f3 are involved in the hepatic disposition of FEx in mice55'56) and
MRP2 mediates the absorption of FEX in humans57'58). These reports suggest that
efflux transporters other than P-gp, such as Mrp2, might be involved in the absorption
of FEX in mice and that the differences in the RTV boosting effects on these
transporters may result in the species differences observed in the pharmacokinetics of
FEX.
  An additional experiment was performed using mouse liver and intestinal
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microsomes to confirm the result obtained in the in vivo study. The fourfold increase
in the AUC for SQV was predicted from the in vitro Ki value for intravenously
administered SQV, which is consistent with the results of the in vivo study. This
result indicates that the inhibitory effect of RTV in the liver is mainly attributable to
the inhibition of metabolic enzymes with a minor contribution on the inhibition of
influx transporters in the liver. On the other hand, a significant increase in the AUCi.f
for PRV was observed after the oral administration of 50 mglkg RTV in the in vivo
study. According to the package information ofKaretra@, which is a PI formed by the
combination of lopinavir and RTV, there are no reports that Karetra@ enhances the
plasma concentration of PRV. However, it has been reported that the AUC for
rosuvastatin, a substrate of OATPIBI, is increased twofold by its coadministration
with Karetra@59). In this report, they concluded this interaction might be mediated by
the inhibition by lopinavir and!or ritonavir of rosuvastatin uptake at the level of
absorption by BCRP or at the level of uptake into the hepatocytes by OATPIBI, by
both, or by neither.
  After the oral administration of SQV together with RTV, a ninefold increase in the
AUC for SQV was predicted from the in vitro Ki value, and this is derived from the
inhibition ofmetabolic enzymes in the liver. From this result, the remaining 36-fold
increase in the AUC was considered to be derived from the inhibition of metabolic
enzymes in the small intestine. This result corresponds to the result obtained in the in
vivo study, and the inhibitory effect of RTV boosting is shown to be higher in the small
intestine than in the liver.
5. Conclusion
  RTV mainly affects the first-pass effect in the small intestine, increasing the
bioavailability of orally administered SQV. The effects of RTV boosting are same
between in humans and in mice. However, the cyp isoforms involved in the
metabolism of SQV in mice differ from those in human.
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SUMMARY
    Currently, most drugs are developed as oral formulations and the intestinal
absorption has become important for understanding the pharmacokinetics of orally
administered drugs. Recent significant advances in the research and technology have
revealed the expression of various metabolic enzymes and transporters in the small
intestine, and these findings make it complex the understanding of intestinal
absorption. However, to obtain the appropriate efficacy and avoid an unexpected
adverse event, underlying mechanism involved in the pharmacokinetic of xenobiotics
is significantly important.
  In chapter 1, the characteristics of SASP transport in the mouse intestine were
investigated. SASP is used as a probe substrate ofBCRP and the recent clinical study
indicated the nonlinearity of SASP pharmacokinetic. The absorptive clearance of
SASP did not change in a concentration-dependent manner in wild-type mice. By
contrast, the absorptive clearance of SASP decreased significantly in a
concentration-dependent manner in the presence of Ko134 which is an inhibitor of
BCRP. Similar results were obtained in Bcrp'/' mice. These results suggest the
possible involvement of some influx transporters in the intestinal absorption of SASP
and both the influx and efflux transporters are involved in the intestinal absorption of
SASP, which would explain why the absorptive clearance did not appear to change at
various SASP concentrations in wild-type mice.
  In chapter 2, the extent to which RTV's inhibition of drug transporters andlor
CYP3A contributes to the increased oral bioavailability in mice was investigated by
using each probe substrate. RTV dramatically increases the bioavailability of a
variety of concurrently administered drugs by inhibition of metabolic enzymes and
drug transporters and used as RTV boosting for HIV treatment. Escalating doses of
RTV had dose-dependent effects on the pharmacokinetics of orally administered SQV
and the increase in the AUC for SQV was 325-fold after its coadministration with RTV.
As a result, Fa'Fg increased 38-fold, whereas Fh increased only twofold. These results
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indicate ritonavir mainly affects the first-pass effect of SQV in the small intestine,
increasing the bioavailability of orally administered SQV. In addition, similar result
was demonstrated by the prediction using the the in vitro Ki value. Furthermore, the
AUC for the probe substrates MDZ, FEX, and PRV increased after the oral
administration of RTV by only five-, 13-, and sevenfold, respectively. Moreover, the
AUC for SQV was affected negligibly by ITZ which was an inhibitor of CYP3A in
human.
  In conclusion, the intestinal absorption of SASP involved both the influx and effiux
transporters. Moreover, RTV mainly affects the first-pass effect ofSQV in the small
intestine, increasing the bioavailability oforally administered SQV. Furthermore, cyp
isoforms other than CYP3A, which contribute to the metabolism of saquinavir in
human, are involved in the metabolism of saquinavir in mice. In this thesis, the
pharmacokinetics of the oral drugs which metabolic enzymes and drug transporters are
involved was analyzed using the probe substrates, and the usefu1 basic knowledge
utilized for future pharmacokinetic analysis was acquired.
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